Mechanism of multidrug resistance of human small cell lung cancer cell line H446/VP

Chinese Medical Journal

Volumn 123, Issue 22, 2010, Pages 3299-3303

  Wang, Yan Ling ^a   Yan, Yun Li ^a   Zhou, Na Jing ^a   Han, Shuo ^a   Zhao, Jun Xia ^a   Cao, Cui Li ^a   Lü, Yu Hong ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

Etoposide; Multidrug resistance; Small cell lung cancer; Topoisomerase II

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; DNA TOPOISOMERASE (ATP HYDROLYSING); ETOPOSIDE; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; PROTEIN BAX; PROTEIN BCL 2;

ARTICLE; CANCER RESISTANCE; CELL VIABILITY; CONTROLLED STUDY; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IC 50; IMMUNOCYTOCHEMISTRY; LUNG SMALL CELL CANCER; MULTIDRUG RESISTANCE; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING;

ANTIGENS, NEOPLASM; BLOTTING, WESTERN; CELL LINE, TUMOR; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; IMMUNOHISTOCHEMISTRY; P-GLYCOPROTEIN; PROTO-ONCOGENE PROTEINS C-BCL-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SMALL CELL LUNG CARCINOMA;

EID: 79251517383     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2010.22.024     Document Type: Article

References (15)

1. Fischer B, Arcaro A. Current status of clinical trials for small cell lung cancer. Rev Recent Clin Trials 2008; 3: 40-61.
2. You B, Tranchand B, Girard P, Falandry C, Ribba B, Chabaud S, et al. Etoposide pharmacokinetics and survival in patients with small cell lung cancer: a multicentre study. Lung Cancer 2008; 62: 261-272.
3. Ferraldeschi R, Baka S, Jyoti B, Faivre-Finn C, Thatcher N, Lorigan P. Modern management of small-cell lung cancer. Drugs 2007; 67: 2135-2152.
4. Zhang HJ, Yan YL, Zheng LF, Fan P. Establishment and characterization of an etoposide-resistant human small cell lung cancer cell line H446/VP. Tumor (Chin) 2004; 24: 233-236.
5. Das CM, Aguilera D, Vasquez H, Prasad P, Zhang M, Wolff JE, et al. Valproic acid induces p21 and topoisomerase-II (α/β) expression and synergistically enhances etoposide cytotoxicity in human glioblastoma cell lines. J Neuro Oncol 2007; 85: 159-170.
6. Coss A, Tosetto M, Fox EJ, Sapetto-Rebow B, Gorman S, Kennedy BN, et al. Increased topoisomerase II alpha expression in colorectal cancer is associated with advanced disease and chemotherapeutic resistance via inhibition of apoptosis. Cancer Lett 2009; 276: 228-238.
7. López-Lazaro M, Willmore E, Austin CA. Cells lacking DNA topoisomerase II beta are resistant to genistein. J Nat Prod 2007; 70: 763-767.
8. Uesaka T, Shono T, Kuga D, Suzuki SO, Niiro H, Miyamoto K, et al. Enhanced expression of DNA topoisomerase II genes in human medulloblastoma and its possible association with etoposide sensitivity. J Neurooncol 2007; 84: 119-129.
9. Bleibel WK, Duan S, Huang RS, Kistner EO, Shukla SJ, Wu X, et al. Identification of genomic regions contributing to etoposide-induced cytotoxicity. Hum Genet 2009; 125: 173-180.
10. Andoh T, Nishizawa M, Hida T, Ariyoshi Y, Takahashi T, Ueda R. Reduced expression of DNA topoisomerase II confers resistance to etoposide (VP-16) in small cell lung cancer cell lines established from a refractory tumor of a patient and by in vitro selection. Oncol Res 1996; 8: 229-238.
11. Sohn JW, Lee SY, Lee SJ, Kim EJ, Cha SI, Kim CH, et al. MDR1 polymorphisms predict the response to etoposide-cisplatin combination chemotherapy in small cell lung cancer. Jpn J Clin Oncol 2006; 36: 137-141.
12. Canitrot Y, Bichat F, Cole SP, Deeley RG, Gerlach JH, Bastian G, et al. Multidrug resistance genes (MRP) and MDR1 expression in small cell lung cancer xenografts: relationship with response to chemotherapy. Cancer Lett 1998; 130: 133-141.
13. Rodriguez-Nieto S, Zhivotovsky B. Role of alterations in the apoptotic machinery in sensitivity of cancer cells to treatment. Curr Pharm Des 2006; 12: 4411-4425.
14. Ilievska PB, Smickova S, Jovanovska CS, Zafirovska IB, Stefanovski T, Petrusevska G. Bcl-2 as a prognostic factor for survival in small-cell lung cancer. Prilozi 2009; 29: 281-294.
15. Tahir SK, Yang X, Anderson MG, Morgan-Lappe SE, Sarthy AV, Chen J, et al. Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737. Cancer Res 2007; 67: 1176-1183.